Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | Evolution & goals of GvHD prophylaxis strategies

Rebecca Gonzalez • 16 Feb 2023
Tandem Meetings 2023
General Abatacept Anti-thymocyte globulin Antibodies Cyclophosphamide Mycophenolate mofetil Rituximab Ruxolitinib Sirolimus Tacrolimus

Rebecca Gonzalez, PharmD, BCOP, Moffitt Cancer Center, Tampa, FL, discusses the evolution of graft-versus-host disease (GvHD) prophylaxis strategies, commenting on the importance of moving towards strategies that help optimize T regulatory cell (Treg) concentrations, thus limiting both acute and chronic GvHD. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rebecca Gonzalez

4:50
Impact of belumosudil on tacrolimus & sirolimus pharmacokinetics in patients with chronic GvHD
Rebecca Gonzalez • 16 Feb 2023
3:36
Latest advances in GvHD prophylaxis: TAC/MMF/PTCy & abatacept
Rebecca Gonzalez • 16 Feb 2023
1:47
The impact of belumosudil in patients with chronic GvHD
Rebecca Gonzalez • 16 Feb 2023

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals